Compliance
Customers don't need to clear documents through internal review or negotiate confidentiality before running an analysis.
For private equity
Make antitrust risk a pricing input, not a closing problem.
Taimet is purpose-built for merger antitrust - a full analysis in 10-25 minutes, on exclusively public data, for platform deals, add-ons, and cross-sector portfolios.
The difference between early termination and a second request is not just legal fees. It is months of timeline, uncertain close, and compressed returns. Taimet gives you the regulatory read before you have access to anything from the target, so you can price the risk or walk away before diligence spend is in motion.
Regulatory risk is a deal-economics problem.
Private equity moves across sectors faster than any one team can maintain permanent expertise in every market. And the buy-and-build strategies that drive portfolio returns can also compound antitrust exposure with each add-on. Antitrust risk may not surface clearly until after the deal team has invested meaningful time, outside advisors are engaged, and the economics are already taking shape. By then, risk is no longer an input - it is a disruption.
Taimet is designed for the stage PE actually needs it: target evaluation, IC prep, and early deal screening. In 10-25 minutes, using public data, Taimet provides a structured antitrust read before the diligence record is complete. That means regulatory risk can be priced, questioned, or escalated early - before it becomes a late-stage surprise.
How Taimet fits PE deal flow
Expert-grade antitrust at the speed of a competitive process, on public data, across any industry.
Pre-LOI screening: kill or deepen before diligence compounds
In 10-25 minutes, Taimet surfaces markets, competitive overlaps, vertical exposure, and state-level enforcement context. Enough to decide whether regulatory risk is a pricing factor, a diligence priority, or a reason to pass. Run it across five targets in an afternoon - before committing a week of team time to the wrong one.
A prediction of the regulatory outcome, not just a risk flag
The Taimet Score™ maps to six real-world outcome bands: early termination, pull and refile, second request, remedies, trial on the merits, adverse decision. Early termination versus a second request has direct consequences for timeline, closing certainty, and the regulatory strategy budget itself. That prediction should be in the model before the LOI goes out.
Built for any transaction type
Taimet identifies transaction type automatically and applies the right analytical framework to each structure. Horizontal overlaps, vertical exposure, and cumulative concentration across a platform strategy all get structured treatment, not a single-paragraph summary. Taimet analyzes every industry, from cat food to caskets.
IC-ready analysis with cited sources
Taimet produces a full written report - markets, theory of harm, enforcement context, and a scored outcome prediction - structured for professional readers, not formatted like a chat transcript. Cited public sources let your team spot-check the claims that matter before the IC conversation, not after.
Pressure-test the deal, don't just describe it
Taimet doesn't stop at identifying overlaps - it highlights where the transaction is most likely to face resistance and why. That allows deal teams to focus diligence, refine structure, or walk away based on where the real regulatory pressure sits.
No party uploads, no confidentiality complications
Taimet works on exclusively public information. No data rooms, no party-supplied materials, no NDA review for the tool itself. The analysis works before you have target access, and it cannot be shaped by what parties choose to provide. One fewer step in the process, with one fewer compliance question.
Six bands, calibrated to real-world outcomes
Every analysis produces a 0-100 Taimet Score™, mapped to six interpretive bands. The bands are designed to reflect the actual range of merger outcomes - from quick clearance through trial on the merits to adverse decision - as an experienced attorney would predict them.
Score Ranges
Low riskHigh risk
1–25Early termination
Parties may be granted early termination of the HSR waiting period when the transaction is unlikely to substantially lessen competition.
26–50Pull and refile
The merging parties can withdraw and refile to give enforcers more time, so review often extends beyond the usual 30-day window.
51–70Second request
These deals carry a higher risk of a second request and a longer review; toward the top of the band, negotiated outcomes become more common.
71–85Remedies
A complaint and structural or behavioral remedies are plausible, with lower scores leaning toward settlement and higher scores toward litigation.
86–95Trial on the merits
Substantial antitrust effects with few likely remedies can produce a litigated trial on the merits.
96–100Adverse decision
Strong anticompetitive concerns and limited remedies may lead to trial and an adverse decision against the merging parties.
1 to 25, Early termination: Parties may be granted early termination of the HSR waiting period when the transaction is unlikely to substantially lessen competition. 26 to 50, Pull and refile: The merging parties can withdraw and refile to give enforcers more time, so review often extends beyond the usual 30-day window. 51 to 70, Second request: These deals carry a higher risk of a second request and a longer review; toward the top of the band, negotiated outcomes become more common. 71 to 85, Remedies: A complaint and structural or behavioral remedies are plausible, with lower scores leaning toward settlement and higher scores toward litigation. 86 to 95, Trial on the merits: Substantial antitrust effects with few likely remedies can produce a litigated trial on the merits. 96 to 100, Adverse decision: Strong anticompetitive concerns and limited remedies may lead to trial and an adverse decision against the merging parties.
Built by an enforcer who spent twenty years inside the work
Taimet's Founder, Gwendolyn Lindsay Cooley, served nearly two decades as Wisconsin's Assistant Attorney General for Antitrust. She chaired the National Association of Attorneys General Multistate Antitrust Task Force, leading coalitions of state and federal enforcers and collaborating with international counterparts. She co-led the trial team for the States' challenge to T-Mobile/Sprint - one of the highest-profile telecom antitrust cases in recent history.
Most AI products are built by AI researchers who consult lawyers. Taimet was built by a lawyer who spent two decades doing this work, in partnership with an engineer with two decades building production software. The reasoning encoded into the system isn't theoretical. It's hers.
Read more about Gwendolyn's background →
Things only an enforcer would know
There is a small body of working knowledge - the kind held by people who have spent years doing this - that determines how mergers actually get analyzed. None of it is in a textbook. Almost none of it is in an LLM's training data. All of it is in Taimet.
Pharmaceutical market definition
Small-molecule drugs are in the same market only if they share an identical molecular structure and are AB-rated for each other. Biologics are in the same market only if they’re biosimilars and treat the same disease. The distinction determines whether a pharma deal looks like a horizontal overlap or a non-issue. Most analysts don’t know it. Taimet does - and applies it automatically.
State enforcement patterns
Different state attorneys general challenge different kinds of mergers. Some are aggressive on hospital consolidation. Others on agriculture. Others on tech. Taimet knows which jurisdictions are likely to act on which transactions, which state-level enforcement theories apply, and which mergers will draw multistate coalitions.
Where the evidence actually lives
Pricing-power evidence often surfaces in investor presentations. Foreclosure intent shows up in board materials. Public statements about competitive intent surface in regulatory filings before they show up in press releases. Taimet knows where to look - because the person who designed it spent two decades looking there.
These are three examples among dozens. The full set is what makes the difference between an analysis that sounds expert and one that actually is.
An analyst that doesn't have to specialize
Taimet identifies the transaction structure automatically - horizontal, vertical, conglomerate, cross-market, cluster market, private equity, or any combination. Most real deals involve more than one structure at once. A private equity roll-up in a health services market may face horizontal overlap, vertical foreclosure concerns, and cumulative competition effects simultaneously. The system applies the right analytical frameworks for each without the user needing to classify the deal first.
Horizontal
Companies with overlap in both product and geographic market, competing directly in the same space.
Vertical
Companies in a direct or indirect vertical relationship within the same supply chain.
Conglomerate
An acquisition in an unrelated industry, with no economic relationship between the companies.
Cluster market
Multiple products sold together as a bundle (e.g., supermarket goods, hospital services).
Cross-market
Companies selling identical products but operating in separate, non-overlapping geographic markets.
Private equity
A private equity firm acquiring a company in a market where it has no existing holdings.
Across every industry
The FTC specializes. The DOJ specializes. Taimet doesn't.
Both federal agencies build their enforcement staffs around industry teams. A human analyst has to choose what to know deeply. That structural constraint doesn't apply to Taimet. The same system that analyzes a pharmaceutical merger - where market definition turns on molecular structure and AB-rating - analyzes a semiconductor deal, a regional hospital consolidation, or a mining joint venture. No configuration required. For the first time, the analytical breadth of the entire merger landscape is available to a single analyst.
PharmaceuticalsSemiconductorsHealthcare & HospitalsBig TechMining & ResourcesFinancial ServicesAgricultureReal EstateManufacturingTelecommunicationsRetail & Consumer GoodsEnergy & UtilitiesMedia & EntertainmentDefense & AerospaceTransportation & LogisticsFood & BeverageInsuranceBiotechnology
A screening tool, not a substitute for judgment
Taimet was designed first as an initial screening tool. For PE deal teams, it surfaces regulatory risk early enough to make it a pricing input - before the LOI, before outside counsel is engaged, before meaningful diligence spend is committed. Run it on five targets in an afternoon instead of staffing one for a week.
But Taimet stops where human judgment begins. Deal teams still structure the acquisition. Counsel still builds the clearance strategy. The system is built to sharpen expert judgment, not replace it - and every output is designed to be reviewed, challenged, and built upon by the human in the loop.
What Taimet does
- Analyzes broad and narrow market overlaps
- Reasons like an expert antitrust attorney
- Calculates HHI and estimated market shares
- Performs comprehensive vertical analysis
- Assesses state AG and political exposure
- Reviews related actions and prior conduct
- Predicts likely enforcement outcome with a 0-100 score
- Cites sources throughout
What Taimet doesn't do
- Conduct economic modeling (e.g., diversion ratios, merger simulation)
- Accept or process party-supplied documents
- Operate as a chatbot or interactive Q&A tool
- Replace the judgment of expert counsel, analysts, or enforcers
We only need the names of the companies
Taimet doesn't accept uploads. We don't process party-supplied documents. We don't ingest deal materials. To run an analysis, the system needs only the names of the merging companies. This serves three purposes at once:
Security
No party-confidential data ever enters the system, which means none can leak from it.
Anti-gaming
Taimet can't be used as a sandbox to reverse-engineer which factors lower a score. The integrity of the analysis can't be manipulated.
Hallucination is the central problem with using general-purpose LLMs for high-stakes legal and economic analysis. The errors sound plausible. They're hard for a human reviewer to catch. And once a wrong claim enters the pipeline, downstream analysis builds on top of it.
Taimet addresses this with verification passes throughout the analysis. Citation-checking agents confirm that claims are actually supported by the cited sources. Reasoning-consistency checks compare conclusions across agents. Claims without source support are flagged. Different stages of the pipeline cross-validate each other before the report is finalized.
The system checks its own work.
What practitioners are saying
“When you are reviewing multiple transactions with a small team, the constraint isn't judgment, it's time. A tool like this does not replace discretion, but it immediately shows you where to focus it.”
“Reflecting the creator's experience of regulatory matters, the depth of analysis, and more importantly the consistency, is far beyond anything we've seen from general tools. It's genuinely useful for investment decisions.”
“Even as antitrust enforcement becomes less predictable, the need for a clear, consistent view of risk hasn't gone away - if anything, it's more important. Taimet is one of the few tools that brings real structure to that uncertainty. We've been early believers, and it's become a critical part of how we advise investors in live situations.”
“Taimet is the first tool I've seen that genuinely closes the gap between legal analysis and investor needs. It delivers clarity where there used to be noise, and it's quickly become indispensable to how we advise our clients.”
Video WalkthroughSee how Taimet works,
See how Taimet works,
and how easy it is to use.
For private equity
The regulatory read your deal economics depend on.
Early termination, second request, or remedies - the outcome shapes your timeline, your returns, and your regulatory strategy budget. Taimet predicts it in 10-25 minutes, on public data, with a report that holds up when it matters. Screen targets before exclusivity, walk into IC with a sourced regulatory view, and price the real risk before it prices you.
10-25 min
Full analysis, not a summary
0-100
Proprietary risk score
~15 hours saved
Per merger analysis
